financetom
Business
financetom
/
Business
/
Lilly's cancer drug more effective than AbbVie's in head-to-head study
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Lilly's cancer drug more effective than AbbVie's in head-to-head study
Jul 29, 2025 4:14 AM

July 29 (Reuters) - Eli Lilly ( LLY ) said on Tuesday

its drug, Jaypirca, was more effective in a head-to-head study

against AbbVie's ( ABBV ) Imbruvica when tested in patients with

a type of blood cancer.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Copyright 2023-2026 - www.financetom.com All Rights Reserved